 Stopping criteria will be established for immunogenic and thrombogenic events. If a single case of any these events is reported after a subject being dosed with study drug, any further enrollment and dosing of subjects in the study will be suspended until the event can be adequately assessed by the sponsor. The enrollment and dosing will only reassume if the sponsor deems it is safe to do so. 